Experiencia de la vida real con el uso de mesalazina MMX en pacientes mexicanos con CUCI en dos centros de tercer nivel
Resumen: Introducción y objetivos: Los 5-aminosalicilatos, principalmente la mesalazina, es la primera opción de tratamiento para la colitis ulcerosa crónica idiopática (CUCI) con actividad de leve a moderada. Con la nueva formulación de mesalazina multimatrix (MMX) se observan altas tasas de induc...
Main Authors: | J.K. Yamamoto-Furusho, N.N. Parra-Holguín |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Elsevier
2022-07-01
|
Series: | Revista de Gastroenterología de México |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0375090621000586 |
Similar Items
-
Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01) -
Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01) -
Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01) -
Epidemiología de COVID-19 en un hospital de tercer nivel mexicano
by: César A. Arce-Salinas, et al.
Published: (2021-07-01) -
A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
by: Mimari Kanazawa, et al.
Published: (2022-02-01)